Today: July 22, 2024
June 16, 2024
1 min read

JP Morgan’s Biotech Fund Secures Half a Billion in Debut

Article Summary


– J.P. Morgan Private Capital closed its inaugural Biotechnology Fund at over $500 million.

– The fund received strong support from a variety of investors across different regions and aims to invest in private biotechnology companies.

J.P. Morgan Private Capital recently announced the final closing of its first Life Sciences Private Capital offering, the 270 Life Sciences Private Capital Fund I. Led by Chief Investment Officer Stephen Squinto, Ph.D. and Managing Partner Gaurav Gupta, M.D., M.S.E., the fund exceeded its $500 million target with support from investors globally.

The fund focuses on investing in private biotechnology companies across various therapeutic areas and geographies, including cardiometabolic disease, oncology, immunology, and genetic medicines. Utilizing the scale and resources of J.P. Morgan, the fund aims to add value to its portfolio companies.

J.P. Morgan Private Capital provides customized financing solutions for private companies in the venture and growth investing sectors, spanning consumer, technology, and life sciences industries. The 270 Life Sciences Private Capital Fund I is the latest addition to the platform, following the successful closure of the J.P. Morgan Growth Equity Partners fund in April 2023.

Key Quotes:

“We are pleased to announce the close of our inaugural fund, which was raised in just over a year, almost two times faster than our peers in the past decade. As investors and company builders, we are strongly positioned at J.P. Morgan Private Capital to identify and support highly innovative companies that can shape the future of how patients are treated.”

– Dr. Stephen Squinto, Chief Investment Officer and Managing Partner of J.P. Morgan Life Sciences Private Capital

“We are grateful for the support of our investors, and for the key contributions of our strategic advisors and internal team members, as we announce the close of our inaugural life sciences venture capital fund. As the biotechnology industry enters the next era of scientific discovery, we strive to become a partner of choice for world-class researchers and entrepreneurs.”

– Gaurav Gupta, M.D., M.S.E., Managing Partner of J.P. Morgan Life Sciences Private Capital

Source: Pulse 2.0

Previous Story

The Rise of Deep Tech in the Venture Capital World

Next Story

US Investors Eye Japan’s Defense Startups for Potential Growth

Latest from Blog

Antheia Secures $17M Investment

TLDR: Antheia, a pharmaceutical ingredient manufacturer based in Menlo Park, CA, raised $17M in funding. The funding included a non-dilutive two-year project agreement up to $11M through the BioMaP Consortium. Antheia, led
Go toTop